This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Integra Rides High on Product Launches, Competition Rife
by Zacks Equity Research
Integra LifeSciences' (IART) latest launch of new sizes of SurgiMend and PriMatrix and Omnigraft as well as continued growth in private label products is encouraging.
Henry Schein to Offer CAS' Fully-Automated Cognivue Device
by Zacks Equity Research
Henry Schein (HSIC) is consistently working toward boosting its Medical segment.
Hill-Rom (HRC) Rides on Product Launches, Competition Rife
by Zacks Equity Research
Hill-Rom (HRC) focuses on product innovation through research and development. Its product launches slated for the fourth quarter are boosting investors' confidence.
AmerisourceBergen's PharMEDium Slows Down, Competition Rife
by Zacks Equity Research
AmerisourceBergen'S (ABC) growth story is expected to be stunted by tepid performance at PharMEDium. Also steep competition is a cause of concern.
Integra LifeSciences' SurgiMend PRS Meshed Boosts ADM Line
by Zacks Equity Research
Advancing its portfolio of acellular dermal tissue matrix for plastic and reconstructive surgery, including breast reconstruction, Integra LifeSciences (IART) launched SurgiMend PRS Meshed in Europe.
AngioDynamicis' (ANGO) Solero MTA System to Drive Growth
by Zacks Equity Research
Growth in the core Angiographic Catheter business is also likely to fortify the company's footprint in the global space.
Amedisys' Arm Buys Intercity Home Care, Boosts U.S. Base
by Zacks Equity Research
Amedisys' (AMED) encouraging efforts put the Personal Care business on growth track. This segment lives up to a strong performance with the integration of several recent tuck-in acquisitions.
Boston Scientific's Apama Deal to Boost Electrophysiology Arm
by Zacks Equity Research
Boston Scientific's (BSX) Apama Medical addition is expected to strengthen its suite of arrhythmia solutions under the Electrophysiology sub-segment.
Quest Diagnostics Buys 2 Outreach Labs, Widens Customer Base
by Zacks Equity Research
Quest Diagnostics (DGX) completes acquisition of outreach laboratory services of two Hartford HealthCare hospitals. The deal is expected to widen the network of the company.
Abbott to Gain from Alere's Takeover Due for Oct 3 Closure
by Zacks Equity Research
Alere's acquisition would help Abbott (ABT) explore new channels and geographies, including forays into fast growing outlets like doctors' offices, clinics, pharmacies and at-home testing.